Regeneron director George L. Sing sells 21,129 shares

George L. Sing's reported sales comprised nine lots, alongside exercises of options from two awards.

Available on EDGAR 11/04/2026 - 04:12 PM EST Accepted by SEC EDGAR 11/04/2026 - 04:11 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Regeneron Pharmaceuticals director George L. Sing exercised non-qualified stock options on November 2, 2026, acquiring 7,830 common shares at an exercise price of $376.69 and 7,439 shares at $380.95. He sold 21,129 common shares that day in nine reported lots: 1,224 at a volume-weighted average price of $960.57, 540 at $961.85, 2,522 at $962.61, 4,338 at $963.47, 2,670 at $964.57, 7,073 at $965.38, 1,522 at $966.27, 1,040 at $967.07, and 200 at $970.18. No Rule 10b5-1 plan is reported.

The 7,830-share option expires January 3, 2027, and the 7,439-share option expires January 2, 2028. The options vested in three equal annual installments, commencing one year after grant.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 13 txns

Insider SING GEORGE L

Role Director

Sold 21,129 shs ($20.38M)

Approx. gross sale proceeds $20.38M

Approx. exercise cost $5.78M

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right to buy) F10	7,830	$0.00	$0.00
Exercise	Non-Qualified Stock Option (right to buy) F10	7,439	$0.00	$0.00
Exercise	Common Stock	7,830	$376.69	$2.95M
Exercise	Common Stock	7,439	$380.95	$2.83M
Sale	Common Stock F1	1,224	$960.57	$1.18M
Sale	Common Stock F2	540	$961.85	$519K
Sale	Common Stock F3	2,522	$962.61	$2.43M
Sale	Common Stock F4	4,338	$963.47	$4.18M
Sale	Common Stock F5	2,670	$964.57	$2.58M
Sale	Common Stock F6	7,073	$965.38	$6.83M
Sale	Common Stock F7	1,522	$966.27	$1.47M
Sale	Common Stock F8	1,040	$967.07	$1.01M
Sale	Common Stock F9	200	$970.18	$194K
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 25,147 shares (Direct); Common Stock — 750 shares (Indirect, by Spouse); Common Stock — 400 shares (Indirect, by Spouse/Cust Son); Common Stock — 1,000 shares (Indirect, by Trust for Son)

Footnotes (10)

1. F1. Represents volume-weighted average price of sales of 1,224 shares of Company stock on November 2, 2026 at prices ranging from $960.03 to $960.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
2. F2. Represents volume-weighted average price of sales of 540 shares of Company stock on November 2, 2026 at prices ranging from $961.76 to $961.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
3. F3. Represents volume-weighted average price of sales of 2,522 shares of Company stock on November 2, 2026 at prices ranging from $962.07 to $962.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
4. F4. Represents volume-weighted average price of sales of 4,338 shares of Company stock on November 2, 2026 at prices ranging from $963.00 to $963.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
5. F5. Represents volume-weighted average price of sales of 2,670 shares of Company stock on November 2, 2026 at prices ranging from $964.10 to $964.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
6. F6. Represents volume-weighted average price of sales of 7,073 shares of Company stock on November 2, 2026 at prices ranging from $965.00 to $965.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
7. F7. Represents volume-weighted average price of sales of 1,522 shares of Company stock on November 2, 2026 at prices ranging from $966.02 to $966.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
8. F8. Represents volume-weighted average price of sales of 1,040 shares of Company stock on November 2, 2026 at prices ranging from $967.00 to $967.26. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
9. F9. Represents volume-weighted average price of sales of 200 shares of Company stock on November 2, 2026 at prices ranging from $970.16 to $970.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
10. F10. The stock option vested in three equal annual installments, commencing one year after the date of grant.

Key Figures

Shares acquired on option exercise: 7,830 shares at $376.69 per share Shares acquired on option exercise: 7,439 shares at $380.95 per share Shares sold: 21,129 shares +5 more

8 metrics

Shares acquired on option exercise 7,830 shares at $376.69 per share November 2, 2026

Shares acquired on option exercise 7,439 shares at $380.95 per share November 2, 2026

Shares sold 21,129 shares November 2, 2026

Reported sale lot 1,224 shares at $960.57 per share Volume-weighted average price on November 2, 2026

Reported sale lot 200 shares at $970.18 per share Volume-weighted average price on November 2, 2026

Common shares held by spouse 750 shares Indirect holding listed

Common shares held by spouse/custodial son 400 shares Indirect holding listed

Common shares held by trust for son 1,000 shares Indirect holding listed

Key Terms

Non-Qualified Stock Option, volume-weighted average price, annual installments

3 terms

Non-Qualified Stock Option financial

"Non-Qualified Stock Option (right to buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

volume-weighted average price financial

"Represents volume-weighted average price of sales of 1,224 shares"

Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.

annual installments financial

"vested in three equal annual installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many REGN shares did George L. Sing sell, and at what prices?

George L. Sing reported sales totaling 21,129 shares on November 2, 2026. The nine lots had reported volume-weighted average prices of $960.57, $961.85, $962.61, $963.47, $964.57, $965.38, $966.27, $967.07, and $970.18 per share, respectively.

What indirect REGN shareholdings were listed for George L. Sing's family and trust?

The report lists 750 common shares held by his spouse, 400 held by his spouse/custodial son, and 1,000 held by a trust for his son. These are listed as indirect holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SING GEORGE L

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN NEW YORK 10591

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/02/2026		M		7,830	A	$376.69	38,837	D
Common Stock	11/02/2026		M		7,439	A	$380.95	46,276	D
Common Stock	11/02/2026		S		1,224	D	$960.57(1)	45,052	D
Common Stock	11/02/2026		S		540	D	$961.85(2)	44,512	D
Common Stock	11/02/2026		S		2,522	D	$962.61(3)	41,990	D
Common Stock	11/02/2026		S		4,338	D	$963.47(4)	37,652	D
Common Stock	11/02/2026		S		2,670	D	$964.57(5)	34,982	D
Common Stock	11/02/2026		S		7,073	D	$965.38(6)	27,909	D
Common Stock	11/02/2026		S		1,522	D	$966.27(7)	26,387	D
Common Stock	11/02/2026		S		1,040	D	$967.07(8)	25,347	D
Common Stock	11/02/2026		S		200	D	$970.18(9)	25,147	D
Common Stock								750	I	by Spouse
Common Stock								400	I	by Spouse/Cust Son
Common Stock								1,000	I	by Trust for Son

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$376.69	11/02/2026		M			7,830	(10)	01/03/2027	Common Stock	7,830	$0.0	0	D
Non-Qualified Stock Option (right to buy)	$380.95	11/02/2026		M			7,439	(10)	01/02/2028	Common Stock	7,439	$0.0	0	D

Explanation of Responses:

1. Represents volume-weighted average price of sales of 1,224 shares of Company stock on November 2, 2026 at prices ranging from $960.03 to $960.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

2. Represents volume-weighted average price of sales of 540 shares of Company stock on November 2, 2026 at prices ranging from $961.76 to $961.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

3. Represents volume-weighted average price of sales of 2,522 shares of Company stock on November 2, 2026 at prices ranging from $962.07 to $962.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

4. Represents volume-weighted average price of sales of 4,338 shares of Company stock on November 2, 2026 at prices ranging from $963.00 to $963.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

5. Represents volume-weighted average price of sales of 2,670 shares of Company stock on November 2, 2026 at prices ranging from $964.10 to $964.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

6. Represents volume-weighted average price of sales of 7,073 shares of Company stock on November 2, 2026 at prices ranging from $965.00 to $965.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

7. Represents volume-weighted average price of sales of 1,522 shares of Company stock on November 2, 2026 at prices ranging from $966.02 to $966.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

8. Represents volume-weighted average price of sales of 1,040 shares of Company stock on November 2, 2026 at prices ranging from $967.00 to $967.26. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

9. Represents volume-weighted average price of sales of 200 shares of Company stock on November 2, 2026 at prices ranging from $970.16 to $970.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.

10. The stock option vested in three equal annual installments, commencing one year after the date of grant.

	/s/ George L. Sing	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)